



Press release from Emotra AB (publ)

Göteborg, March 9, 2020

Emotra is close to sealing collaboration agreement for clinical studies

We are working to expand our portfolio and are close to achieving further milestones in our new indication area for EDOR® test – depression relapse. After preliminary discussions, we have initiated negotiations with a Swedish university. At the same time, we are negotiating with several groups of researchers in Europe and North America.

One aspect of these collaboration negotiations would mean that the researchers will take partial responsibility for completion of the studies. The aim of the agreement is to support Emotra with the development of study protocols as well as with coordination, management and processing of the study data. This would help ensure Emotra's access to high-quality data that can be published and distributed.

We are in discussions with research groups in Europe and North America for further studies, with the goal of producing more data that underscore hyporeactivity as a biomarker for mental illness. These projects feature different types of collaboration and partnership. We will be publishing more information about them once the negotiations are finalised.

"Access to biomarkers that can help healthcare providers identify those patients who risk depression relapse is one of the greatest challenges facing the psychiatric profession today. It is estimated that half of all patients who recover from their first depression will suffer one or two more episodes in their lives, and that 80 per cent of patients who have experienced two episodes will suffer a new relapse. This affects a large number of patients and the cost to society is very high. This is where EDOR test can provide biological data that helps the doctors treating such patients prevent relapses," says Daniel Poté, Emotra AB's CEO.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se